A new item has been added to the shopping cart

×
×

Tell to a friend

Your Name:
E-mail of your friend:
Message:
Captcha CAPTCHA code
Enter the text in the image above

×

Already a subscriber? Log in now for online Access.

×

Artículo Tomo 71, Número. 4, Mayo 2018

Archivos Españoles de Urología

Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.

Authors: Venancio Chantada-Abal, Cristina Chantada-Tirado, Leticia Lamas-Díaz, Francisco Caramés- Masana, Anselmo Damián Villegas-Piguave y Nuria Villar-Vázquez.

Arch. Esp. Urol. 2018; 71 (4): 453-457 Keywords: B

Vol. 71, Number. 4, May 2018

Bacilus Calmette-Guerin (BCG) administered intravesical is an effective therapy in non muscle invasive bladder cancer (NMIBC), but it presents limitations regarding recurrence and toxicity. For years, many case series have been published where sequential therapy with BCG and Mitomycin C (MMC) was tried. In this article, we perform a review of the data supplied by these articles with the aim to determine the safety and efficacy of combination, and what is the group of patients it should be indicated. Many studies show that combination therapy did not cause more toxicity and improved the interval free of disease with decrease of tumor progression compared to BCG or MMC monotherapy. Therefore, a combination of MMC and BCG therapy seems safe, but more clinical studies are required for a future evaluation.


Only subscribers


Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |